AstraZeneca recognises the rapid development of science and innovation in China related to discovery research and drug development.
We are actively seeking strategic alliance opportunities and R&D collaborations with Chinese academia as well as pharmaceutical and biotechnology companies.
Key areas of partnering interest
• CNS, pain, oncology, respiratory, inflammation, diabetes, obesity, atherosclerosis, serious bacterial and fungal
infection, and special viral infections (e.g. RSV, HBV, HCV)
• Chemistry, protein biochemistry, predictive toxicology and
other skill and technology areas relevant for pharmaceutical R&D
• Late stage or in-market products from companies that are under-leveraged in China
Contacts
Richard Wang - AstraZeneca Innovation Centre China
E-mail:
firstname.lastname@astrazeneca.com
- Replace with authentic names
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
